November 2008 - Page 65 of 76

MondayNov 03, 2008 4:38 am

Oramed Pharmaceuticals Inc. (OTC BB: ORMP)

Oramed Pharmaceuticals Inc. (OTC BB: ORMP), a commercial drug development company, is applying proprietary expertise in integrative pharmacology to potentially discover new uses for drug candidates. Currently, the company is committing their efforts to developing certain compounds for new uses. Compounds in Ore’s development pipeline include: romazarit (for metabolic disorders), tiapamil (for treatment of diseases of the central nervous system), and GL1001 (for inflammatory bowel disease). For further information, visit the Company's web site at www.oramed.com.

MondayNov 03, 2008 4:38 am

Opexa Therapeutics, Inc. (NASDAQ: OPXA)

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company, has focused their efforts on the development of patient-specific cellular therapies designed to treat autoimmune diseases such as multiple sclerosis (MS) and diabetes. Tovaxin, the company’s lead product candidate, is an innovative T-cell vaccine used to treat MS. Results from the Phase IIb study have shown a positive trend in reducing annualized relapse rate for patients treated with the drug compared to placebo. For further information, visit the Company's web site at www.opexatherapeutics.com.

MondayNov 03, 2008 4:37 am

Bioheart, Inc.’s (NASDAQ: BHRT)

Bioheart, Inc.’s (NASDAQ: BHRT) primary mission is to become a leading company focused on discovering, developing and commercializing innovative, autologous cell therapies and such devices. A number of cell therapies and related devices designed to treat chronic and acute heart damage consist of the company’s product line. They believe the market for treating patients in NYHA Class II or NYHA Class III heart failure is significant as there are approximately 5.2 million patients with heart failure in the United States alone. For further information, visit the Company's web site at www.bioheartinc.com.

MondayNov 03, 2008 4:37 am

OncoVista Innovative Therapies, Inc. (OTC BB: OVIT)

OncoVista Innovative Therapies, Inc. (OTC BB: OVIT), a biopharmaceutical company, is focused on developing and commercializing therapies targeted towards cancer that are designed to provide more efficiency while being less toxic. By combining their extensive in-house pre-clinical and clinical know-how with a global drug development network, the company intends to see rapid and cost-effective regulatory approval and commercialization of innovative therapies. For further information, visit the Company's web site at www.oncovista.com.

MondayNov 03, 2008 4:37 am

BioDelivery Sciences International, Inc. (NASDAQ: BDSI)

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company, is focused on utilizing its innovative and proprietary patented drug delivery technologies to develop and commercialize new applications of proven therapeutics. Currently, the company is developing formulations of pharmaceuticals primarily targeted at treatment opportunities in areas such as pain and infections. For further information, visit the Company's web site at www.biodeliverysciences.com.

MondayNov 03, 2008 4:36 am

Oncothyreon, Inc. (NASDAQ: ONTY)

Oncothyreon, Inc. (NASDAQ: ONTY), a biotechnology company, is committed to the development of oncology products designed to improve the lives and outcomes of cancer patients. Currently, the company is in the process of developing multiple therapeutic candidates targeting cancer in specific and effective ways. With headquarters in Seattle, Washington, their pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. For further information, visit the Company's web site at www.oncothyreon.com.

MondayNov 03, 2008 4:36 am

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), an integrated biopharmaceutical company, utilizes crystallography and structure-based drug design to develop a deep pipeline of innovative therapeutics. Currently, the company is progressing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. The U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. have all formed strategic alliances with the company and validate its scientific foundation and the utility of its product candidates. For further information, visit the Company's web site at www.biocryst.com .

MondayNov 03, 2008 4:36 am

Oncolytics Biotech, Inc. (NASDAQ: ONCY)

Oncolytics Biotech, Inc. (NASDAQ: ONCY) has focused their efforts on the discovery and development of pharmaceutical products designed to treat of a broad range of human cancers. With headquarters in Calgary, Alberta, Canada, the Company was formed in 1998 to investigate the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, which happens to be one of the most common families of genetic defects leading to cancer. For further information, visit the Company's web site at www.oncolytics.com.

MondayNov 03, 2008 4:35 am

Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI)

Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI) is dedicated to developing innovative technologies that provide safer and more effective options to patients in areas with significant, but unmet medical needs. The company is primarily focused on the areas of biosurgical and passive immunotherapy products. By utilizing their proprietary protein purification technology, novel development capabilities, and manufacturing expertise, the company aims to develop treatments of choice in their respective therapeutic areas. For further information, visit the Company's web site at www.omrix.com.

MondayNov 03, 2008 4:35 am

Bio-Bridge Science, Inc. (OTC BB: BGES)

Bio-Bridge Science, Inc. (OTC BB: BGES) is a development stage biotechnology company committed to engaging in the commercial development of vaccines for the prevention and treatment of human infectious diseases. Currently, the company is focused on developing and commercializing HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV). The HIV vaccines developed by Bio-Bridge are designed for both preventive and therapeutic purposes. For further information, visit the Company's web site at www.bio-bridge-science.com.

Site Search

Company Search

Month: November 2008

Oramed Pharmaceuticals Inc. (OTC BB: ORMP)

Opexa Therapeutics, Inc. (NASDAQ: OPXA)

Bioheart, Inc.’s (NASDAQ: BHRT)

OncoVista Innovative Therapies, Inc. (OTC BB: OVIT)

BioDelivery Sciences International, Inc. (NASDAQ: BDSI)

Oncothyreon, Inc. (NASDAQ: ONTY)

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

Oncolytics Biotech, Inc. (NASDAQ: ONCY)

Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI)

Bio-Bridge Science, Inc. (OTC BB: BGES)

Market Basics

Newsletter Publishers

Public Companies